




Docket No.: 241244US0CONT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RE: Application Serial No.: 10/667,783  
Applicants: Miroslav SMRIGA, et al.  
Filing Date: September 23, 2003  
For: AGENTS AGAINST STRESS-INDUCED DISEASES  
Group Art Unit: 1614  
Examiner: Lewis, A.A.

SIR:

Attached hereto for filing are the following papers:

**Response to Restriction Requirement**

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.


Stephen G. Baxter  
Registration No. 32,884

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

Vincent K. Shier, Ph.D.  
Registration No. 50,552



DOCKET NO.: 241244US0CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

RE APPLICATION OF:

:

Miroslav SMRIGA, et al.

: GROUP ART UNIT: 1614

SERIAL NO.: 10/667,783

:

FILED: SEPTEMBER 23, 2003

: EXAMINER: LEWIS, A.A.

FOR: AGENTS AGAINST STRESS-INDUCED DISEASES

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VA 22313-1450

SIR:

Responsive to the Official Action dated May 24, 2006, Applicants elect, with traverse, Group II, Claims 1-23, drawn to a method of preventing, ameliorating, blocking or treating stress-induced diseases comprising administering a pharmaceutical composition containing lysine, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I: Claims 24-26, drawn to a pharmaceutical composition containing lysine;  
and

Group II: Claims 1-23, drawn to a method of preventing, ameliorating, blocking or treating stress-induced diseases comprising administering a pharmaceutical composition containing lysine.

Applicants elect, with traverse, Group II, Claims 1-23, drawn to a method of preventing, ameliorating, blocking or treating stress-induced diseases comprising administering a pharmaceutical composition containing lysine, for further prosecution.